A peer-reviewed study from China Medical University’s Shengjing Hospital and Columbia University Medical Center has demonstrated the ability of a new point-of-care test from Shuwen Biotech, Deqing, China, for detecting preeclampsia at a high level of accuracy in women admitted to the hospital for any reason.1
In the study, researchers collected urine from 1,532 pregnant women hospitalized at 20 to 41 weeks gestation, regardless of the reason for hospitalization, and prospectively tested misfolded proteins in their urine using Shuwen’s patented point-of-care test device. Results showed a very high screening performance in a first-to-be-studied Chinese population.
“We at Shuwen are grateful to our collaborators for their hard and diligent work over the last few years to demonstrate how our company principles of innovation, patent protection, and international collaboration can lead to tangible and outstanding clinical value for patients and other stakeholders,” says Jay Z. Zhang, MS, JD, chairman and chief executive officer at Shuwen Biotech. “The data published in this paper reinforce the clinical importance of point-of-care testing in preeclampsia globally. We look forward to continuing to build this important clinical body of evidence.”
The test kit is CE marked and available for sales and clinical use in an increasing number of countries as regulatory processes progress across the world.
For more information, visit Shuwen Biotech.
Reference
1. Li XM, Liu XM, Xu J, Du J, Cuckle H. Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins. PLoS One. 2020;15(5):e0233214; doi: 10.1371/journal.pone.0233214.
